Comparison Table: Triptans for Migraine (online only)

The Medical Letter on Drugs and Therapeutics

ONLINE
ONLY
ARTICLE

June 12, 2023

View Complete Issue Table of Contents 2019

Download PDF: US English

Disclosures & Objectives Disclosures & Objectives

Show Related Terms Hide Related Terms

View Complete Issue

Send Article Feedback

Med Lett Drugs Ther. 2023 Jun 12;65(1678):e97-9 doi:10.58347/tml.2023.1678b

Disclosures

Principal Faculty

Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.
Brinda M. Shah, Pharm.D., Consulting Editor has disclosed no relevant financial relationships.

Additional Contributor(s)

Michael Viscusi, Pharm.D., Associate Editor has disclosed no relevant financial relationships.

Objective(s)

Upon completion of this activity, the participant will be able to:

Explain the current approach to the management of migraine.
Discuss the pharmacologic options available for acute and preventive treatment of migraine and compare them based on their efficacy, dosage and administration, potential adverse effects, and drug interactions.
Determine the most appropriate therapy given the individual presentation of a patient with migraine.

Select a term to see related articles almotriptan eletriptan Frova frovatriptan Imitrex Maxalt migraine naratriptan Onzetra Xsail propranolol Relpax rizatriptan sumatriptan Tosymra Zembrace

View the Comparison Table: Triptans for Migraine

Download PDF: US English | Canadian-English

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

This article has been freely provided.